Marinus Pharmaceuticals shares are trading lower after Oppenheimer downgraded the stock from Outperform to Perform and announced a $14 price target. Additionally, multiple firms lowered their respective price targets on the stock.
Portfolio Pulse from Benzinga Newsdesk
Marinus Pharmaceuticals' stock has been downgraded from Outperform to Perform by Oppenheimer, with a new price target of $14. Other firms have also lowered their price targets for the stock.
August 11, 2023 | 7:27 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Marinus Pharmaceuticals has been downgraded by Oppenheimer and other firms have lowered their price targets, which could negatively impact the stock price.
The downgrade by Oppenheimer and the lowering of price targets by multiple firms indicate a less optimistic outlook for Marinus Pharmaceuticals. This could lead to a decrease in the stock price as investors adjust their expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100